Choice of nucleoside inhibitors in antiretroviral therapy regimens for HIV-infected patients treated for chronic hepatitis C



Cite item

Full Text

Abstract

The rates of development of virologic and biochemical responses and the incidence and degree of hematological disorders within the first 12 weeks of treatment for chronic hepatitis C (CHC) were determined in patients with HIV infection depending on the used agents from a group of nucleotide reverse transcriptase inhibitors as part of an antiretroviral therapy (ART) regimen. Seventy-eight patients with HIV infection and CHC who received ARVT for at least 3 months were followed up. According to the ARVT regimen, the patients were divided into 2 groups: 1) 46 took phosphaside incorporated into an ARVT regimen; 2) 32 received stavudine or abacavir.
Among all the patients, rapid and complete early virologic responses (rEVR and cEVR) were obtained in 52 and 79% of cases, respectively. When phosphaside was used in the ART regimens, the rates of rEVR and cEVR development were significantly higher (95.8 and 53.3% of cases, respectively). The phosphaside-treated patients with hepatitis C virus (HCV) genotype 1 also had a high cEVR rate. The absolute majority of patients with HCV genotype 3 showed cEVR irrespective of the ART regimen. Following 12-week treatment for CHC, 83.3-95.5% had a reduction in alanine aminotransferase levels to the values observed in healthy individuals, which was also indicative of the efficiency of treatment. In the HIV infected patients treated for CHC, the use of phosphaside, stavudine, or abacavir was safe in terms of hematological complications. In the patients receiving phosphaside, the reduction in hemoglobin levels was more considerable. Evolving hematological disorders required no changes in the ART regimen or reductions in the dose of pegylated interferon or ribavirin.

About the authors

N Yu Gankina

Krasnoyarsk Territorial Center for Prevention and Control of AIDS and Infectious Diseases

Krasnoyarsk Territorial Center for Prevention and Control of AIDS and Infectious Diseases

A V Kravchenko

Federal Research and Methodological Center for AIDS Prevention and Control, Moscow

Email: kravtchenko@hivrussia.net
Federal Research and Methodological Center for AIDS Prevention and Control, Moscow

U A Kuimova

Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare, Moscow

Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare, Moscow

V G Kanestri

Federal Research and Methodological Center for AIDS Prevention and Control, Moscow

Federal Research and Methodological Center for AIDS Prevention and Control, Moscow

References

  1. Диспансерное наблюдение, лечение и профилактика вирусных гепатитов у подростков и взрослых, больных ВИЧ-инфекцией: Метод. рекомендации Федерального НМЦ ПБ СПИД / Кравченко А. В., Ганкина Н. Ю., Канестри В. Г. и др. - М., 2007.
  2. Канестри В. Г., Кравченко А. В., Ганкина Н. Ю. и др. Гепатотоксичность у больных ВИЧ-инфекцией, получавших высокоактивную антиретровирусную терапию // Эпидемиол. и инфекц. бол. - 2006. - № 6. - C. 31-34.
  3. Кравченко А. В., Ганкина Н. Ю., Канестри В. Г. Особенности антиретровирусной терапии при сочетании ВИЧ-инфекции и хронического вирусного гепатита // Фарматека. - 2008. - № 19. - С. 10-17.
  4. Максимов С. Л., Иванова Л. И., Кравченко А. В. и др. Особенности терапии хронического гепатита C пегилированным интерфероном α-2a и рибавирином у больных ВИЧ-инфекцией // Тер. арх. - 2007. - Т. 79, № 11. - С. 40-44.
  5. Сюткин В. Е. Новые возможности повышения эффективности противовирусной терапии больных хроническим гепатитом C // Инфекц. бол. - 2009. - Т. 7, № 2. - С. 55- 59.
  6. Gonzalez-Garcia J. J., Berenguer J., Condes E. et al. The use of TDF + 3TC/FTC is associated with an improved response to pegylated interferon + ribavirin in HIV/HCV-co-infected patients receiving HAART: The Gesida 50/06 Study Group // 15th Conference on Retroviruses and Opportunistic Infections (CROI 2008). Boston, MA. Feb. 3-6, 2008. - Boston, 2008. - Abstr. 1076.
  7. Khaykin P., Vogel M., Voigt E. et al. Impact of different ART regimens on efficacy and safety of standard HCV treatment in HIV/HCV co-infected patients // 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 22-25 July 2007, Sydney, Australia. - Sydney, 2007. - Abstr. MOPEB056.
  8. Mira J., Lopez-Cortes L., Barreiro P. et al. Efficacy of pegylated interferon + ribavirin treatment in HIV/HCV-co-infected patients receiving abacavir + lamivudine or tenofovir + either lamivudine or emtricitabine as nucleoside analogue backbone // CROI 2008. - Abstr. 1074.
  9. Soriano V., Puoti M., Sulkowski M. et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV Internationals Panel // AIDS. - 2007. - Vol. 21. - P. 1073-1089.
  10. Vachon M.-L. C., Qazi N., Dieterich D. T. HCV treatment challenges in patients co-infected with HIV // Future HIV Ther. - 2009. - Vol. 3, N 1. - P. 87-100.

Copyright (c) 2010 Eco-vector



Свидетельство о регистрации СМИ № 014448 от 08.02.1996 г. выдано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор). 
Свидетельство о регистрации СМИ ЭЛ № ФС 77 - 80652 от 15.03.2021 г. выдано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies